Medicines Co. Stock
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0.880% | -4.547% | 11.619% | 0.248% | 1.250% | -16.852% | -8.698% |
| Opko Health Inc. | 4.010% | 3.394% | -3.179% | -19.132% | -17.106% | -13.843% | -70.008% |
| Amicus Therapeutics Inc. | 0.610% | -2.924% | 7.097% | -10.270% | -9.290% | -29.816% | -56.995% |
Comments
News
Meet the Biotech Stock That Just Jumped 251% Higher
Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its
BeOne Medicines (ONC) Q2 EPS Soars 924%
BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue